دورية أكاديمية
أعرض في EDS

Evaluating the Urinary Exosome microRNA Profile of von Hippel Lindau Syndrome Patients with Clear Cell Renal Cell Carcinoma.

التفاصيل البيبلوغرافية
العنوان: Evaluating the Urinary Exosome microRNA Profile of von Hippel Lindau Syndrome Patients with Clear Cell Renal Cell Carcinoma.
المؤلفون: Walter-Rodriguez B; Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA., Ricketts CJ; Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA., Linehan WM; Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA., Merino MJ; Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
المصدر: Genes [Genes (Basel)] 2024 Jul 11; Vol. 15 (7). Date of Electronic Publication: 2024 Jul 11.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101551097 Publication Model: Electronic Cited Medium: Internet ISSN: 2073-4425 (Electronic) Linking ISSN: 20734425 NLM ISO Abbreviation: Genes (Basel) Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Basel : MDPI
مواضيع طبية MeSH: Carcinoma, Renal Cell*/genetics , Carcinoma, Renal Cell*/urine , Exosomes*/genetics , Exosomes*/metabolism , von Hippel-Lindau Disease*/genetics , von Hippel-Lindau Disease*/urine , von Hippel-Lindau Disease*/complications , MicroRNAs*/urine , MicroRNAs*/genetics , Kidney Neoplasms*/genetics , Kidney Neoplasms*/urine , Biomarkers, Tumor*/urine , Biomarkers, Tumor*/genetics, Humans ; Female ; Male ; Middle Aged ; Adult ; Gene Expression Regulation, Neoplastic ; Aged
مستخلص: Introduction: Renal cell carcinoma is one of the ten more common malignant tumors worldwide, with a high incidence and mortality rate. Kidney cancer frequently presents at an advanced stage, and it is almost invariably fatal. Much progress has been made in identifying molecular targets for therapy in the hope of improving survival rates, but still, we have no good markers for early detection or progression of the disease. Von Hippel Lindau syndrome (VHL) is an autosomal dominant cancer hereditary syndrome in which affected individuals are at risk of developing bilateral and multifocal renal cell carcinomas (RCC) as well as other tumors. These patients provide an ideal platform to investigate the potential of urinary exosomal miRNA biomarkers in the early development of ccRCC, as these patients are regularly imaged and tumors are actively monitored until the tumor reaches 3 cm before surgical excision. This allows for pre- and post-surgical urine collection and comparison to excised tumor tissues. Studying different biomarkers in urine can provide comprehensive molecular profiling available to patients and physicians and can be a great source of additional tumor genetic information.
Methods: Pre- and postoperative urine samples were obtained from a cohort of VHL patients undergoing surveillance and surgical excision of ccRCCs, and exosomes were extracted. MicroRNA-Seq analysis was performed on miRNA extracted from both urine-derived exosomes and FFPE material from excised ccRCCs.
Results: MicroRNA-Seq analysis highlighted a significant difference in the urinary exosome-derived miRNA expression profiles between VHL patients and normal control individuals. This included decreased expression of the miR-320 family, such as miR-320a, known to be decreased in sporadic ccRCC and suppressed by the HIF1α transcription factor activated by the loss of the VHL gene. MiR-542-5p represented a potential marker of VHL-associated ccRCC that was lowly expressed in normal control urinary exosomes, significantly increased in the preoperative urinary exosomes of tumor-bearing VHL patients, and subsequently reduced to normal levels of expression after tumor excision. In concordance with this, the expression of miR-542-5p was increased in the VHL-associated ccRCC in comparison to the normal kidney.
Conclusions: This study shows the potential for miRNA profiling of exosomes from readily available biofluids to both distinguish VHL patient urine from normal control urine microRNAs and to provide biomarkers for the presence of VHL syndrome-associated ccRCC. Further validation studies are necessary to demonstrate the utility of urinary exosome-derived miRNAs as biomarkers in kidney cancer.
References: Cancer Gene Ther. 2022 May;29(5):573-584. (PMID: 33888871)
Nat Rev Urol. 2010 May;7(5):277-85. (PMID: 20448661)
Eur Urol Focus. 2018 Apr;4(3):412-419. (PMID: 28753793)
Front Cell Dev Biol. 2021 Dec 24;9:775642. (PMID: 35004677)
Mol Cancer. 2022 Feb 18;21(1):56. (PMID: 35180868)
Mol Cancer. 2023 Feb 21;22(1):37. (PMID: 36810071)
PLoS One. 2011;6(9):e25787. (PMID: 21984948)
Signal Transduct Target Ther. 2016 Jan 28;1:15004. (PMID: 29263891)
Nat Commun. 2018 Dec 7;9(1):5228. (PMID: 30531873)
Am J Pathol. 2012 May;180(5):1787-97. (PMID: 22429968)
Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15524-9. (PMID: 12434020)
Cancers (Basel). 2021 May 28;13(11):. (PMID: 34071230)
Onco Targets Ther. 2020 Oct 23;13:10765-10774. (PMID: 33122915)
Adv Exp Med Biol. 2010;685:228-49. (PMID: 20687511)
J Clin Oncol. 2016 Jun 20;34(18):2172-81. (PMID: 27114602)
Front Mol Biosci. 2022 Sep 27;9:916666. (PMID: 36237572)
J Extracell Vesicles. 2021 May;10(7):e12093. (PMID: 34035881)
J Transl Med. 2022 Jan 3;20(1):6. (PMID: 34980158)
J Transl Med. 2012 Mar 22;10:55. (PMID: 22440013)
Sci Rep. 2020 Dec 4;10(1):21290. (PMID: 33277569)
Urol Oncol. 2017 May;35(5):294-299. (PMID: 28089386)
Mol Cancer. 2022 Mar 18;21(1):79. (PMID: 35303879)
Int J Mol Sci. 2013 Jul 16;14(7):14785-99. (PMID: 23863690)
Int J Mol Sci. 2023 Jun 29;24(13):. (PMID: 37446024)
Exp Mol Med. 2023 Jul;55(7):1314-1321. (PMID: 37430087)
Radiology. 1995 Mar;194(3):629-42. (PMID: 7862955)
Biomedicines. 2021 May 23;9(6):. (PMID: 34071109)
Science. 1993 May 28;260(5112):1317-20. (PMID: 8493574)
Biomed Pharmacother. 2019 Mar;111:517-526. (PMID: 30597305)
J Cell Mol Med. 2019 Oct;23(10):6755-6765. (PMID: 31342628)
Semin Diagn Pathol. 2024 Jan;41(1):1-7. (PMID: 38008653)
Eur Urol Focus. 2016 Jun;2(2):210-218. (PMID: 28723537)
Int Urol Nephrol. 2018 May;50(5):851-859. (PMID: 29549624)
Br J Cancer. 2013 Mar 19;108(5):1133-42. (PMID: 23449350)
Nat Rev Urol. 2014 Dec;11(12):688-701. (PMID: 25403245)
Acta Pharm Sin B. 2021 Sep;11(9):2783-2797. (PMID: 34589397)
Lancet Oncol. 2017 Oct;18(10):1386-1396. (PMID: 28870611)
فهرسة مساهمة: Keywords: VHL; ccRCC; liquid biopsy; miRNA; molecular markers; renal cell carcinoma; urinary exosomes; von Hippel Lindau
المشرفين على المادة: 0 (MicroRNAs)
0 (Biomarkers, Tumor)
تواريخ الأحداث: Date Created: 20240727 Date Completed: 20240727 Latest Revision: 20240729
رمز التحديث: 20240729
مُعرف محوري في PubMed: PMC11276299
DOI: 10.3390/genes15070905
PMID: 39062684
قاعدة البيانات: MEDLINE
الوصف
تدمد:2073-4425
DOI:10.3390/genes15070905